Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Over the past years, technological improvements and refinements in magnetic resonance imaging (MRI) hardware have made high-quality diffusion-weighted imaging (DWI) routinely possible for the bowel. DWI is promising for the detection and characterization of lesions in Crohn's disease (CD) and has been advocated as an alternative to intravenous gadolinium-based contrast agents. Furthermore, quantification using the apparent diffusion coefficient may have value as a biomarker of CD activity and has shown promise. In this article we critically review the literature pertaining to the value of DWI in CD for detection, characterization, and quantification of disease activity and complications. Although the body of supportive evidence is growing, it is clear that well-designed, multicenter studies are required before the role of DWI in clinical practice can be fully established. J. Magn. Reson. Imaging 2016;44:1381-1396.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmri.25325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Inflammatory bowel diseases and pregnancy].
Rev Med Suisse
August 2025
Service de gastroentérologie et d'hépatologie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
Inflammatory bowel diseases frequently affect individuals of reproductive age. Optimal management before and during pregnancy is critical for minimizing maternal and fetal complications. Disease remission at the time of conception reduces the risk of flares and adverse pregnancy outcomes.
View Article and Find Full Text PDFPenoscrotal swelling as a presentation of Crohn's disease.
J Surg Case Rep
September 2025
Department of Pediatric Gastroenterology and Hepatology, Bai Jerbai Wadia Hospital for Children, Acharya Dhonde Marg, Parel, Mumbai, Maharashtra 400012, India.
Metastatic Crohn's disease (MCD) is a rare extraintestinal manifestation of Crohn's disease (CD), particularly in pediatric patients. It refers to cutaneous involvement at areas distant and non-contiguous from the bowel. We present a boy with a 1.
View Article and Find Full Text PDFImproved bioavailability of buccal nanoemulsion vitamin D compared to conventional oral supplementation in patients with inflammatory bowel disease: a randomized controlled trial.
Front Med (Lausanne)
August 2025
Internal Clinic, 3rd Medical Faculty, Charles University and University Thomayer Hospital, Prague, Czechia.
Objectives: The absorption of conventional cholecalciferol may be impaired in patients with inflammatory bowel disease (IBD). The bioavailability and optimal dosing of buccally absorbable nanoemulsion vitamin D in this population remain unclear. This study aimed to compare the effects of buccal nanoemulsion and conventional oral vitamin D supplementation on serum 25-hydroxyvitamin D (25OHD) levels in patients with IBD.
View Article and Find Full Text PDFPioneering the IBD specialist nurse role in China: a shared decision-making model for clinical practice innovation.
Front Med (Lausanne)
August 2025
Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Inflammatory bowel disease (IBD) is a chronic condition characterized by the need for highly individualized treatment plans, requiring patients to make numerous complex medical decisions. Shared decision-making (SDM) has proven effective in improving treatment outcomes, patient satisfaction, and adherence in IBD management; however, its clinical implementation remains challenging. In China, formal SDM nurse roles have not yet been established.
View Article and Find Full Text PDFA Therapeutic Tightrope: Managing Coexisting Crohn Disease and Systemic Lupus Erythematosus With Risankizumab.
ACG Case Rep J
September 2025
Department of Rheumatology, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
The coexistence of systemic lupus erythematosus (SLE) and Crohn disease (CD) is rare and presents significant diagnostic and therapeutic challenges due to overlapping clinical, radiologic, and histologic features. We present a 24-year-old woman with SLE, chronic immune thrombocytopenic purpura, and newly diagnosed CD treated with risankizumab, an interleukin-23 inhibitor approved for CD. She achieved complete clinical and radiologic remission of CD without SLE flares over 12 months.
View Article and Find Full Text PDF